Skip to main content
Top
Published in: Clinical & Experimental Metastasis 5/2005

01-09-2005

A PSP94-derived Peptide PCK3145 inhibits MMP-9 Secretion and Triggers CD44 Cell Surface Shedding: Implication in Tumor Metastasis

Authors: Borhane Annabi, Mounia Bouzeghrane, Jean-Christophe Currie, Robert Hawkins, Hélène Dulude, Luc Daigneault, Marcia Ruiz, Jan Wisniewski, Seema Garde, Shafaat A. Rabbani, Chandra Panchal, Jinzi J. Wu, Richard Béliveau, Phd

Published in: Clinical & Experimental Metastasis | Issue 5/2005

Login to get access
Metadata
Title
A PSP94-derived Peptide PCK3145 inhibits MMP-9 Secretion and Triggers CD44 Cell Surface Shedding: Implication in Tumor Metastasis
Authors
Borhane Annabi
Mounia Bouzeghrane
Jean-Christophe Currie
Robert Hawkins
Hélène Dulude
Luc Daigneault
Marcia Ruiz
Jan Wisniewski
Seema Garde
Shafaat A. Rabbani
Chandra Panchal
Jinzi J. Wu
Richard Béliveau, Phd
Publication date
01-09-2005
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 5/2005
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-005-2669-1

Other articles of this Issue 5/2005

Clinical & Experimental Metastasis 5/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine